MedTrace Logo

Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant

NCT04167683 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 144

Last updated 2025-12-08

No results posted yet for this study

Summary

PURPOSE: To investigate the effect of the disease and HSCT on muscle dysfunction and to investigate the prognostic role of muscle dysfunction at critical decision points in patients with hematological diseases referred to hematopoietic stem cell transplant (HSCT).

HSCT: Patients diagnosed with malignant hematological diseases who are referred to myeloablative HSCT, to a myeloablative "reduced toxicity conditioning" regime with Fludarabine and Treosulfane (FluTreo) or to non-myeloablative HSCT.

Conditions

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Jan Christensen, post doc · Department of Occupational- and Physiotherapy, Rigshospitalet

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2026-11-01
Completion
2026-11-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04167683 on ClinicalTrials.gov